Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | MYC | P01106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486470 | 0.86 | LMNA (0.37) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6495545 | 0.85 | HTT (0.42) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6488328 | 0.85 | DRD4 (0.40) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6486075 | 0.85 | LMNA (0.34) | FAAHDRD2DRD3HTR1AHTR7 | |
| SCHEMBL6498194 | 0.85 | HTR2B (0.34) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6486899 | 0.83 | ALDH1A1 (0.33) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6496243 | 0.83 | DRD4 (0.43) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6485909 | 0.83 | TP53 (0.33) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6490571 | 0.83 | DRD4 (0.35) | DRD2DRD3HTR1AHTR7HRH1 | |
| SCHEMBL6484988 | 0.83 | DRD2 (0.32) | DRD2DRD3HTR1AHTR7HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869958-B2 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014909-A1 | FUSED TETRAHYDROPYRIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038960-A1 | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors | MMP9, MMP3, MMP13 | FAAH 3450/4885DRD2 963/4885DRD3 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.